October 28, 2019 / 8:58 PM / 20 days ago

BRIEF-Morphosys Announces End Of Clinical Development Program Of MOR106 In Atopic Dermatitis

Oct 28 (Reuters) - MorphoSys AG:

* ANNOUNCED END OF CLINICAL DEVELOPMENT PROGRAM OF MOR106 IN ATOPIC DERMATITIS

* DECISION WAS BASED ON A LACK OF EFFICACY AND NOT ON SAFETY CONCERNS

* JOINT DECISION BY GALAPAGOS, MORPHOSYS & NOVARTIS, WAS BASED ON INTERIM ANALYSIS FOR FUTILITY THAT WAS PERFORMED IN PHASE 2 IGUANA TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below